Literature DB >> 2104075

Intravenous omeprazole: effect of a loading dose on 24-h intragastric pH.

J Andersen1, M Ström, J Naesdal, K Leire, A Walan.   

Abstract

To determine the effect of three times daily dosing with intravenous omeprazole on intragastric acidity, 24 h intragastric pH was measured continuously with a monocrystalline antimony electrode system in II patients with inactive duodenal ulceration during fasting conditions. After a baseline investigation, two different dosage regimens of intravenous omeprazole were compared in a double-blind crossover study, with regard to their ability to keep the pH greater than or equal to 4 for as long as possible. Success in the individual patient was defined as pH greater than or equal to 4 for at least 90% over the 24-h period. Two doses of omeprazole [40 mg t.d.s. (120 mg) and 80 mg + 40 mg + 40 mg (160 mg)] were compared. Omeprazole (120 mg) increased the median of individual median intragastric 24-h pH from 1.49 to 6.67. The pH was greater than or equal to 4 for greater than or equal to 90% of the 24 h in three of the 11 patients. With omeprazole, 160 mg (a loading dose of 80 mg), the median of individual median intragastric 24-h pH increased to 7.33. The pH was greater than or equal to 4 for greater than or equal to 90% of the 24 h in seven of the 11 patients. Median time to reach pH 4 was 39 min after 40 mg and 20 min after 80 mg omeprazole. An initial loading dose of 80 mg omeprazole seems preferable to 40 mg to achieve a fast and sustained increase in intragastric pH to above 4 in the fasting patient.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104075     DOI: 10.1111/j.1365-2036.1990.tb00450.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects.

Authors:  S Teyssen; S T Chari; J Scheid; M V Singer
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

Authors:  Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  World J Gastrointest Endosc       Date:  2011-03-16

3.  Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

Authors:  J Labenz; U Peitz; C Leusing; B Tillenburg; A L Blum; G Börsch
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

Review 4.  A practical guide to the management of bleeding ulcers.

Authors:  C Villanueva; J Balanzó
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

6.  Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.

Authors:  Josep M Piqué; Faust Feu; Gloria de Prada; Kerstin Röhss; Göran Hasselgren
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy.

Authors:  Hsu-Heng Yen; Chia-Wei Yang; Wei-Wen Su; Maw-Soan Soon; Shun-Sheng Wu; Hwai-Jeng Lin
Journal:  BMC Gastroenterol       Date:  2012-06-08       Impact factor: 3.067

8.  Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review.

Authors:  Mitsushige Sugimoto; Jin Seok Jang; Yashiro Yoshizawa; Satoshi Osawa; Ken Sugimoto; Yoshihiko Sato; Takahisa Furuta
Journal:  Diagn Ther Endosc       Date:  2012-07-18

9.  Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies.

Authors:  Yu Hidaka; Toru Imai; Tomoki Inaba; Tomo Kagawa; Katsuhiro Omae; Shiro Tanaka
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.